<?xml version="1.0" encoding="UTF-8"?>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <front>
    <journal-meta>
      <journal-id journal-id-type="ojs">journal</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Journal For International Medical Graduates</journal-title>
        <abbrev-journal-title xml:lang="en">Journal For International Medical Graduates</abbrev-journal-title>
      </journal-title-group>
      <publisher>
        <publisher-name>California Institute of Behavioral Neurosciences and Psychology</publisher-name>
        <publisher-loc>
          <country>US</country>
          <uri>https://www.cibnp.com</uri>
        </publisher-loc>
      </publisher>
      <issn pub-type="epub">2832-9864</issn>
      <self-uri xlink:href="https://www.jimgs.com/ojs/index.php/journal"/>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">77</article-id>
      <article-categories>
        <subj-group xml:lang="en" subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Xylazine: Zombie Drug Provides a Wakeup Call for the Dangers of Drug Abuse</article-title>
      </title-group>
      <contrib-group content-type="author">
        <contrib corresp="yes">
          <name-alternatives>
            <string-name specific-use="display">Prajwala Nagarajappa</string-name>
            <name name-style="western" specific-use="primary">
              <surname>Nagarajappa</surname>
              <given-names>Prajwala</given-names>
            </name>
          </name-alternatives>
          <email>prajwala.nagarajappa@jimgs.com</email>
        </contrib>
        <contrib>
          <name-alternatives>
            <string-name specific-use="display">Maneeth Mylavarapu</string-name>
            <name name-style="western" specific-use="primary">
              <surname>Mylavarapu</surname>
              <given-names>Maneeth</given-names>
            </name>
          </name-alternatives>
          <email>maneeth.mylavarapu@jimgs.com</email>
        </contrib>
        <contrib>
          <name-alternatives>
            <string-name specific-use="display">Sree Mahathi Chavali</string-name>
            <name name-style="western" specific-use="primary">
              <surname>Chavali</surname>
              <given-names>Sree Mahathi</given-names>
            </name>
          </name-alternatives>
          <email>sree.mahathi.chavali@jimgs.com</email>
        </contrib>
      </contrib-group>
      <pub-date date-type="pub" publication-format="epub">
        <day>08</day>
        <month>05</month>
        <year>2023</year>
      </pub-date>
      <pub-history>
        <event event-type="received">
          <event-desc>Received: <date date-type="received" iso-8601-date="2023-05-08T05:27:47+00:00"><day>8</day><month>5</month><year>2023</year></date></event-desc>
        </event>
      </pub-history>
      <permissions>
        <copyright-statement>Copyright (c) 2023 Journal For International Medical Graduates</copyright-statement>
        <copyright-year>2023</copyright-year>
        <copyright-holder>Journal For International Medical Graduates</copyright-holder>
      </permissions>
      <self-uri xlink:href="https://www.jimgs.com/ojs/index.php/journal/article/view/77"/>
      <kwd-group xml:lang="en">
        <kwd>Xylazine</kwd>
        <kwd>Veterinary tranquilizer</kwd>
        <kwd>Drug abuse</kwd>
        <kwd>Public health</kwd>
        <kwd>Morbidity</kwd>
        <kwd>Overdose prevention</kwd>
      </kwd-group>
      <custom-meta-group/>
    </article-meta>
  </front>
  <body/>
  <back>
    <ref-list>
      <ref id="R1">
        <mixed-citation>National Institute on Drug Abuse: Xylazine. (2022). Accessed: March 24, 2023: https://nida.nih.gov/research-topics/xylazine</mixed-citation>
      </ref>
      <ref id="R2">
        <mixed-citation>GREENE SA, THURMON JC. Xylazine – a review of its pharmacology and use in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics.1988, 11(4):295–313. 10.1111/j.1365-2885.1988.tb00189.x</mixed-citation>
      </ref>
      <ref id="R3">
        <mixed-citation>DEA Joint Intelligence Report: The growing threat of xylazine and its mixture with illicit drugs. (2022). Accessed: March 24, 2023: https://www.dea.gov/sites/default/files/2022-12/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf</mixed-citation>
      </ref>
      <ref id="R4">
        <mixed-citation>Tranq Dope: Animal sedative mixed with Fentanyl brings fresh horror to U.S. drug zones. (2023). Accessed: March 24, 2023: https://www.nytimes.com/2023/01/07/health/fentanyl-xylazine-drug.html</mixed-citation>
      </ref>
      <ref id="R5">
        <mixed-citation>FDA: FDA warns about the risk of xylazine exposure in humans. (2022). Accessed: March 24, 2023: https://www.fda.gov/media/162981/download</mixed-citation>
      </ref>
      <ref id="R6">
        <mixed-citation>Reyes JC, Negrón JL, Colón HM, et al. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health. 2012, 89(3):519-526. 10.1007/s11524-011-9662-6</mixed-citation>
      </ref>
      <ref id="R7">
        <mixed-citation>Xylazine in humans: Congress moves to make 'tranq' drug a controlled substance. (2023). Accessed: May 4, 2023: https://abc7ny.com/xylazine-effects-in-humans-congress-controlled-substance/13043734/</mixed-citation>
      </ref>
      <ref id="R8">
        <mixed-citation>Kariisa M, Patel P, Smith H, Bitting J. Notes from the Field: Xylazine Detection and Involvement in Drug Overdose Deaths — United States, 2019. MMWR Morbidity and Mortality Weekly Report. 2021;70(37):1300-1302. Accessed:May 5, 2023: 10.15585/mmwr.mm7037a4</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
